|Bid||416.30 x 0|
|Ask||415.85 x 0|
|Day's range||400.40 - 417.30|
|52-week range||310.15 - 447.70|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||25.48|
|Forward dividend & yield||10.70 (2.62%)|
|Ex-dividend date||27 Mar 2020|
|1y target est||326.96|
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
It's been a good week for Novo Nordisk A/S (CPH:NOVO B) shareholders, because the company has just released its latest...
Britain's brightest and best drug researchers are packing their bags as clinical trials start to dwindle, leaving a nation renowned as a global leader in pharmaceutical development to face a future in the slow lane. This is a worst-case scenario outlined by some scientists and industry experts in the wake of Brexit, which they say could deprive the country of its role as Europe's leader in early-stage drug research, designing and hosting pan-EU trials. Pamela Kearns, professor of paediatric oncology at the University of Birmingham, worries that over time Britain will in particular lose out in the field of medicines that treat rare diseases and childhood cancers, where trials often need to collaborate and recruit across Europe to find enough patients.
Novo Nordisk's new diabetes pill, Rybelsus, will be covered by Express Scripts Holding Co, one of the largest U.S. pharmacy benefit managers, the Danish drugmaker said on Friday. Pharmacy benefit managers act as middlemen in the drug supply chain, and negotiate discounts on drugs on behalf of health insurers. Depending on the discounts drugmakers are willing to provide, pharmacy benefits managers make decisions about which drugs to include in coverage plans.
Is Novo Nordisk A/S (CPH:NOVO B) a good dividend stock? How can we tell? Dividend paying companies with growing...
European shares clocked their best day in over a week on Friday, as upbeat jobs data from the United States and a surprise bounce in Chinese manufacturing tempered nerves around slowing global growth. U.S. job growth slowed less than expected in October, while a private business survey indicated that China's factory activity unexpectedly expanded at the fastest pace in more than two years last month. The latest data out of China is in contrast to an official survey published on Thursday, which had factory activity shrinking for the sixth straight month in October.
Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...
Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 30 September 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.Since the announcement as of 23 September 2019, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKK Accumulated, last announcement3,951,950 1,372,668,150 23 September 2019130,000362.6247,141,236 24 September 2019130,000360.9246,919,325 25 September 2019125,000358.5444,817,391 26 September 2019125,000358.8044,849,806 27 September 2019125,000354.6044,324,908 Accumulated under the programme4,586,950 1,600,720,816 The details for each transaction made under the share repurchase programme are published on novonordisk.com.With the transactions stated above, Novo Nordisk owns a total of 35,146,994 B shares of DKK 0.20, corresponding to 1.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares. Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 27 September 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 27,987,962 B shares at an average share price of DKK 329.99 per B share equal to a transaction value of DKK 9,235,674,270.Further informationMedia: Anne Margrethe Hauge+45 4442 email@example.com Ken Inchausti (US)+1 609 240 firstname.lastname@example.org Investors: Peter Hugreffe Ankersen+45 3075 email@example.com Valdemar Borum Svarrer+45 3079 firstname.lastname@example.org Ann Søndermølle Rendbæk+45 3075 email@example.com Kristoffer Due Berg (US)+1 609 235 firstname.lastname@example.org Company announcement no. 56 / 2019Attachment * CA190930_Safe_Harbour
Bagsvaerd, Denmark, 20 September 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide tablets), as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.Rybelsus®, the brand name for oral semaglutide in the US, is the first approved glucagon-like peptide-1 (GLP-1) receptor agonist in a tablet. The approval of Rybelsus® is based on the results from 10 PIONEER clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® more effectively lowered blood sugar than sitagliptin and empagliflozin. Furthermore, treatment with Rybelsus® resulted in up to 4.4 kg reduction in body weight. Rybelsus® demonstrated a safe and well-tolerated profile across the PIONEER programme, with the most common adverse event being mild to moderate nausea which diminished over time."We are very excited that we can make the first oral GLP-1 available in the US and thereby expand the treatment options for adults living with type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Novo Nordisk has a very long legacy of developing innovative injectable medicines for people living with diabetes and, with the approval of Rybelsus®, we are now able to bring our innovation into the market for oral antidiabetics."Novo Nordisk plans to make Rybelsus® available to adults with type 2 diabetes in the US in the fourth quarter of 2019.Conference callOn 23 September at 8 am CEST, corresponding to 2 am EDT, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of novonordisk.com.About Rybelsus®Rybelsus® (oral semaglutide) is an analogue of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). Rybelsus® is the first and only GLP-1 receptor agonist (RA) in a tablet. It is administered once daily and is approved for use in two therapeutic dosages, 7 mg and 14 mg.Rybelsus® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency. Furthermore, Rybelsus® has been applied for a separate indication with the FDA for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, with expected review completion by Q1 2020.Further informationMedia: Mette Kruse Danielsen +45 4442 3883 email@example.com Ken Inchausti (US) +1 609 240 9429 firstname.lastname@example.org Investors: Peter Hugreffe Ankersen +45 3075 9085 email@example.com Valdemar Borum Svarrer +45 3079 0301 firstname.lastname@example.org Ann Søndermølle Rendbaek +45 3075 2253 email@example.com Kristoffer Due Berg (US) +1 609 235 2989 firstname.lastname@example.org Company announcement No 54 / 2019 Attachment * PR190920_oral_semaglutide_US_approval
European stocks clocked their fifth straight week of gains on Friday with investors buying into the oil and gas and banking sectors, and Novo Nordisk rising after U.S. approval of its oral diabetes drug. Investors also sought refuge in the so-called defensive sectors such as utilities, real-estate and food and beverages ahead of a week packed with economic data. The United Nations (UN) general assembly will also provide clues on the fallout from attacks on Saudi oil facilities last weekend and indications of a potential meeting between the presidents of Iran and the United States.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.